All Outputs (3)

AB0102 POTENTIAL BIOMARKERS TO PREDICT TNF INHIBITORS OUTCOME IN PSORIATIC ARTHRITIS (2023)
Presentation / Conference
Makos, A., Kuiper, J. H., Amarasena, R., & Kehoe, O. (2023, May). AB0102 POTENTIAL BIOMARKERS TO PREDICT TNF INHIBITORS OUTCOME IN PSORIATIC ARTHRITIS. Paper presented at EULAR 2023 European Congress of Rheumatology, Milan, Italy

Comparative analysis of umbilical cord mesenchymal stromal cells versus their extracellular vesicles for the treatment of inflammatory arthritis (2023)
Presentation / Conference
Davies, R., Mennan, C., Platt, M., Wright, K., & Kehoe, O. (2023, March). Comparative analysis of umbilical cord mesenchymal stromal cells versus their extracellular vesicles for the treatment of inflammatory arthritis. Presented at TERMIS 2023 – European Chapter, Manchester Central Conference Centre Manchester, UK

Hypoxic and pro-inflammatory priming of mesenchymal stem cell-derived extracellular vesicles to reduce disease severity and immune responses in inflammatory arthritis (2021)
Presentation / Conference
Kay, A. G., Treadwell, K., Roach, P., Morgan, R., Lodge, R., Hyland, M., …Kehoe, O. (2021, September). Hypoxic and pro-inflammatory priming of mesenchymal stem cell-derived extracellular vesicles to reduce disease severity and immune responses in inflammatory arthritis. Poster presented at 6th European Congress of Immunology, Virtual meeting

Novel biological therapies have revolutionised the management of Rheumatoid Arthritis (RA) but no cure currently exists. Mesenchymal stem cells (MSCs) immunomodulate inflammatory responses through paracrine signalling, including via secretion... Read More about Hypoxic and pro-inflammatory priming of mesenchymal stem cell-derived extracellular vesicles to reduce disease severity and immune responses in inflammatory arthritis.